-
EP3563868
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3563868
| EP3563868 - PHARMACEUTICAL PREPARATION STABLY COMPRISING CD147 MONOCLONAL ANTIBODY [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 04.10.2019 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 07.07.2018 | Most recent event Tooltip | 14.10.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Jiangsu Pacific Meinuoke Bio-Pharmaceutical Co., Ltd. 128 Hehai West Road Xinbei District Changzhou, Jiangsu 213022 / CN | [2019/45] | Inventor(s) | 01 /
TANG, Hao 128 Hehai West Road Xinbei District Changzhou Jiangsu 213022 / CN | 02 /
FENG, Qiang 128 Hehai West Road Xinbei District Changzhou Jiangsu 213022 / CN | 03 /
CHEN, Xiaochun 128 Hehai West Road Xinbei District Changzhou Jiangsu 213022 / CN | [2019/45] | Representative(s) | Kilburn & Strode LLP Lacon London 84 Theobalds Road Holborn London WC1X 8NL / GB | [N/P] |
| Former [2019/45] | Cornish, Kristina Victoria Joy Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | Application number, filing date | 17887476.4 | 27.12.2017 | [2019/45] | WO2017CN118893 | Priority number, date | CN201611271126 | 30.12.2016 Original published format: CN201611271126 | [2019/45] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018121578 | Date: | 05.07.2018 | Language: | ZH | [2018/27] | Type: | A1 Application with search report | No.: | EP3563868 | Date: | 06.11.2019 | Language: | EN | [2019/45] | Search report(s) | International search report - published on: | CN | 05.07.2018 | (Supplementary) European search report - dispatched on: | EP | 05.03.2021 | Classification | IPC: | A61K39/395, C07K16/30, A61P35/00, A61K9/08, A61K47/12, A61K47/18, A61K47/26, A61K47/36 | [2021/01] | CPC: |
A61P35/00 (EP);
C07K16/2803 (EP,CN,US);
A61K39/39591 (EP);
A61K47/12 (EP,CN,US);
A61K47/183 (CN);
A61K47/22 (US);
A61K47/26 (CN,US);
A61K47/36 (CN);
A61K9/0019 (CN,US);
|
| Former IPC [2019/45] | A61K39/395, C07K16/30, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/45] | Title | German: | PHARMAZEUTISCHES PRÄPARAT, DAS MONOKLONALE CD147-ANTIKÖRPER STABIL ENTHÄLT | [2019/45] | English: | PHARMACEUTICAL PREPARATION STABLY COMPRISING CD147 MONOCLONAL ANTIBODY | [2019/45] | French: | PRÉPARATION PHARMACEUTIQUE COMPRENANT DE MANIERE STABLE UN ANTICORPS MONOCLONAL CD147 | [2019/45] | Entry into regional phase | 05.06.2019 | Translation filed | 05.06.2019 | National basic fee paid | 05.06.2019 | Search fee paid | 05.06.2019 | Designation fee(s) paid | 05.06.2019 | Examination fee paid | Examination procedure | 05.06.2019 | Examination requested [2019/45] | 30.09.2021 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 02.10.2019 | Renewal fee patent year 03 | 13.10.2020 | Renewal fee patent year 04 | 24.11.2021 | Renewal fee patent year 05 | 04.10.2022 | Renewal fee patent year 06 | 13.10.2023 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]CN104086654 (FOURTH MILITARY MEDICAL UNIV) [Y] 2-8 * See e.g. SEQ ID NOs: 3 and 4 *; | [XYI]WO2015160853 (SORRENTO THERAPEUTICS INC [US]) [X] 1,9 * See e.g. the claims; section from line 19 of page 28 to line 14 of page 14, as e.g. page 29, lines 7-19; page 30, lines 20-26; section from line 25 of page 36 to line 25 of page 37 * [Y] 2-8 [I] 2-8; | [IY]US2016271253 (CHANG BYEONG SEON [US]) [I] 1,9 * See e.g. paragrapghs 33, 88, 89 or examples 13, 16 and 17 * [Y] 2-8; | [E]WO2018121580 (CHEN XIAOCHUN [CN]) [E] 1-9* the whole document *; | [IY] - WANG W ET AL, "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, US, (20070101), vol. 96, no. 1, doi:10.1002/JPS.20727, ISSN 0022-3549, pages 1 - 26, XP009084505 [I] 2-8 * See e.g. page 14, right col. * [Y] 2-8 DOI: http://dx.doi.org/10.1002/jps.20727 | [IY] - DAUGHERTY ANN L ET AL, CHAPTER 8: Formulation and delivery issues for monoclonal antibody therapeutics, CURRENT TRENDS IN MONOCLONAL ANTIBODY DEVELOPMENT AND MANUFACTURING, SPRINGER, US, PAGE(S) 103 - 129, (20100101), ISBN 978-0-387-76642-3, XP009180430 [I] 2-8 * See e.g. first paragraph of chapter 4, page 107 * [Y] 2-8 DOI: http://dx.doi.org/10.1007/978-0-387-76643-0_8 |